A synthetic route and intermediate compound of an anticancer drug Cabazitaxel
By using 9-dian-13-acetylbacartine III extracted from Canadian yew as raw material, the synthesis process of Kabatassa was simplified, and the problems of complex process and limited resources in the existing technology were solved, and high purity and Green and environmentally friendly production effect.
Patent Information
- Application Number
- CN202111546238.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-12-16
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2041-12-16
AI Technical Summary
The existing kabatasai synthesis process is complex, the total yield is low, the reaction conditions are harsh, and the resources of 10-deacetylbacartine III are limited, making it difficult to produce on a large scale on industrial scale.
Using 9-Dihydrogen-13-acetylbacartine III extracted from Canadian yew as the starting material, the synthesis of cabatatas is carried out through a series of compound protection, oxidation and deprotection steps, using low-toxic or non-toxic green Synthetic reagents, simplify the process and expand the source of raw materials.
The complex reaction, low yield and high pollution problems in traditional processes were overcome, and the product purity reached more than 99.5%, the process flow was simplified, and highly toxic chemicals were eliminated, which achieved a more green and environmentally friendly synthesis.
Smart Images

Figure CN115057833B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to compound synthesis, and in particular to a new synthesis route and intermediate compound of an anticancer drug, cabazitaxel. Background Art
[0002] Cabazitaxel is a gonadotropin-releasing hormone (GnRH) receptor inhibitor drug, mainly for patients with advanced prostate cancer. It is the first and only second-line treatment for metastatic hormone-refractory prostate cancer that provides significant survival benefits. It is approved by the U.S. Food and Drug Administration for the treatment of advanced prostate cancer and is clinically recommended as the first choice for the treatment of advanced, hormone-resistant prostate cancer when the commonly used advanced prostate cancer drug docetaxel is ineffective or even worsens the condition.
[0003] Patents CN102532065B, CN102675256A, CN103242267B, US5847170, US2007293687A1, EP0817779, EP0817780, FR2732340, US5889043, US6372780, US6387946, WO9630355, WO9630356, etc. describe process routes for synthesizing cabazitaxel from 10-deacetylbaccatin III (10-DAB). These process routes are complicated, with low total yield or harsh reaction conditions that make it difficult to produce on an industrial scale. At the same time, 10-DAB is derived from European yew, and its resources are limited. Therefore, it is urgent to expand the raw material source of cabazitaxel and optimize its synthesis process. Summary of the invention
[0004] In view of the defects of the prior art and the limitation of raw material sources, the present invention uses 9-dihydro-13-acetylbaccatin III (9-DHAB) extracted and separated from Taxus canadensis, which is more abundant in resources, as a starting material to synthesize cabazitaxel, and provides a synthetic route and intermediate compound of the anticancer drug cabazitaxel.
[0005] The technical solution adopted by the present invention is: a synthesis route and intermediate compound of the anticancer drug cabazitaxel, including:
[0006] A compound having a structure shown in formula 1:
[0007]
[0008] Wherein R1 is a hydrogen atom or a suitable hydroxyl protecting group;
[0009] R2 is a hydrogen atom or a suitable hydroxyl protecting group;
[0010] R3 is a hydrogen atom or a suitable hydroxy protecting group.
[0011] Preferably, the suitable hydroxyl protecting group is selected from C1-C 25 Ether, C1-C 25 Substituted methyl ethers, C1-C 25 Substituted ethyl ethers, C1-C 25 Acyl, C1-C 25 Haloacyl, C1-C 25 Benzyl ether, C1-C 25 Silane ether, C1-C 25 Esters, C1-C 25 Carbonate, C1-C 25 Sulfonate esters.
[0012] Preferably, the suitable hydroxy protecting group is selected from methyl, methoxymethyl, benzyloxymethyl, tetrahydropyranyl, tetrahydrofuranyl, 2-(trimethylsilyl)ethoxymethyl, 1-ethoxyethyl, 1-(2-chloroethoxy)ethyl, 2,2,2-trichloroethyl, tert-butyl, allyl, propargyl, benzyl, p-methoxybenzyl, diphenylmethyl, triphenylmethyl, trimethylsilyl, triethylsilyl, triisopropylsilyl, dimethylisopropylsilyl, diethylisopropylsilyl, dimethylmethoxysilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, tribenzylsilyl, triphenylsilyl, diphenylmethylsilyl, methylbenzyl, methylcarbonyl, ethylcarbonyl, methoxymethylcarbonyl, trichloroethoxycarbonyl, benzylcarbonyl, benzyloxycarbonyl, allylsulfonyl, methylsulfonyl, and p-phenylsulfonyl.
[0013] Preferably, R1 is methyl.
[0014] Preferably, R2 is methyl.
[0015] Preferably, R3 is acetyl.
[0016] The present invention also provides a compound having a structure shown in Formula 2:
[0017]
[0018] Wherein R1 is a hydrogen atom or a suitable hydroxyl protecting group;
[0019] R2 is a hydrogen atom or a suitable hydroxyl protecting group;
[0020] R3 is a hydrogen atom or a suitable hydroxy protecting group.
[0021] In a preferred embodiment of the present invention, the suitable hydroxyl protecting group is selected from C1-C 25 Ether, C1-C 25 Substituted methyl ethers, C1-C 25 Substituted ethyl ethers, C1-C 25Acyl, C1-C 25 Haloacyl, C1-C 25 Benzyl ether, C1-C 25 Silane ether, C1-C 25 Esters, C1-C 25 Carbonate, C1-C 25 Sulfonate esters.
[0022] In a preferred embodiment of the present invention, the suitable hydroxy protecting group is selected from methyl, methoxymethyl, benzyloxymethyl, tetrahydropyranyl, tetrahydrofuranyl, 2-(trimethylsilyl)ethoxymethyl, 1-ethoxyethyl, 1-(2-chloroethoxy)ethyl, 2,2,2-trichloroethyl, tert-butyl, allyl, propargyl, benzyl, p-methoxybenzyl, diphenylmethyl, triphenylmethyl, trimethylsilyl, triethylsilyl, triisopropylsilyl, dimethylisopropylsilyl, diethylisopropylsilyl, dimethylmethoxysilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, tribenzylsilyl, triphenylsilyl, diphenylmethylsilyl, methylbenzyl, methylcarbonyl, ethylcarbonyl, methoxymethylcarbonyl, trichloroethoxycarbonyl, benzylcarbonyl, benzyloxycarbonyl, allylsulfonyl, methylsulfonyl, and p-phenylsulfonyl.
[0023] Preferably, R1 is methyl.
[0024] Preferably, R2 is methyl.
[0025] Preferably, R3 is acetyl.
[0026] The present invention also provides a compound having a structure shown in Formula 3:
[0027]
[0028] The present invention also provides a process for preparing the compound shown in Formula 3, comprising the following steps: reacting an oxidant with a compound having a molecular formula shown in Formula 4,
[0029]
[0030] Wherein R1 is a hydrogen atom or a suitable hydroxyl protecting group;
[0031] R2 is a hydrogen atom or a suitable hydroxyl protecting group;
[0032] R3 is a hydrogen atom or a suitable hydroxy protecting group.
[0033] In a preferred embodiment of the present invention, the suitable hydroxyl protecting group is selected from C1-C 25 Ether, C1-C 25 Substituted methyl ethers, C1-C 25 Substituted ethyl ethers, C1-C 25 Acyl, C1-C25 Haloacyl, C1-C 25 Benzyl ether, C1-C 25 Silane ether, C1-C 25 Esters, C1-C 25 Carbonate, C1-C 25 Sulfonate esters.
[0034] In a preferred embodiment of the present invention, the suitable hydroxy protecting group is selected from methyl, methoxymethyl, benzyloxymethyl, tetrahydropyranyl, tetrahydrofuranyl, 2-(trimethylsilyl)ethoxymethyl, 1-ethoxyethyl, 1-(2-chloroethoxy)ethyl, 2,2,2-trichloroethyl, tert-butyl, allyl, propargyl, benzyl, p-methoxybenzyl, diphenylmethyl, triphenylmethyl, trimethylsilyl, triethylsilyl, triisopropylsilyl, dimethylisopropylsilyl, diethylisopropylsilyl, dimethylmethoxysilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, tribenzylsilyl, triphenylsilyl, diphenylmethylsilyl, methylbenzyl, methylcarbonyl, ethylcarbonyl, methoxymethylcarbonyl, trichloroethoxycarbonyl, benzylcarbonyl, benzyloxycarbonyl, allylsulfonyl, methylsulfonyl, and p-phenylsulfonyl.
[0035] Preferably, R1 is methyl.
[0036] Preferably, R2 is methyl.
[0037] Preferably, R3 is acetyl.
[0038] In a preferred embodiment of the present invention, the oxidant is selected from Dess-Martin periodinane, Colin's reagent, Swern's reagent, John's reagent, pyridinium chlorochromate (PCC), pyridinium dichromate (PDC), chromium dioxide (CrO2) and tetrapropylammonium perruthenate (TPAP).
[0039] The present invention also provides a preparation process for converting 9-dihydro-13-acetylbaccatin III (9-DHAB) into a taxane derivative, comprising the following steps: removing the acetyl group at position 10 of 9-dihydro-13-acetylbaccatin III and oxidizing the hydroxyl group at position 9.
[0040] In a preferred embodiment of the present invention, the oxidation step includes adding the following oxidants: Dess-Martin periodinane, Colin's reagent, Swern's reagent, John's reagent, pyridinium chlorochromate (PCC), pyridinium dichromate (PDC), chromium dioxide (CrO2) and tetra-n-propylammonium perruthenate (TPAP).
[0041] The present invention also provides a synthetic route of cabazitaxel, which is characterized by comprising the following steps:
[0042] (a): removing the 10-position acetyl group of 9-dihydro-13-acetylbaccatin III to obtain 9-dihydro-10-deacetyl-13-acetylbaccatin III;
[0043] (b): protecting the 7-, 10-hydroxyl groups of 9-dihydro-10-deacetyl-13-acetylbaccatin III with a suitable protecting group to obtain a protected intermediate;
[0044] (c) Oxidation of the 9-hydroxyl group of the protected intermediate using a suitable oxidizing agent.
[0045] In a preferred embodiment of the present invention, the protecting groups include: benzyl, C1-C 25 Substituted benzyl, benzyl formate, C1-C 25 Substituted benzyl formate, phenylsulfonyl, C1-C 25 Substituted phenylsulfonyl, methyl, methoxymethyl, C1-C 25 Alkyl, C1-C 25 Substituted alkyl, benzoyl, C1-C 25 Substituted benzoyl, C1-C 25 Trialkylsilyl, trimethylsilyl, triethylsilyl, triisopropylsilyl, dimethylisopropylsilyl, diethylisopropylsilyl, dimethylmethoxysilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, tribenzylsilyl, triphenylsilyl, diphenylmethylsilyl, methyldiphenylsilyl, benzyloxycarbonyl, C1-C 25 Silane ether, C1-C 25 Esters, C1-C 25 Carbonate, C1-C 25 Sulfonate esters.
[0046] In a preferred embodiment of the present invention, the oxidant includes: Dess-Martin periodinane, Colin's reagent, Swern's reagent, John's reagent, pyridinium chlorochromate (PCC), pyridinium dichromate (PDC), chromium dioxide (CrO2) and tetrapropylammonium perruthenate (TPAP).
[0047] In a preferred embodiment of the present invention, the step of removing the 13-acetyl group of the intermediate 7,10-dimethoxy-10-deacetyl-13-acetylbaccatin III is further included.
[0048] In a preferred embodiment of the present invention, the removal of the 13-acetyl group is accomplished by using a strong base, including n-butyl lithium, methyl lithium, red aluminum, sodium borohydride, and hydrazine hydrate.
[0049] In a preferred embodiment of the present invention, it further comprises the step of adding a suitable side chain to the 13-position of 7,10-dimethoxy-10-deacetylbaccatin III, and selectively deprotecting to obtain the target compound.
[0050] In a preferred embodiment of the present invention, the selective deprotection is to remove the p-methoxybenzoyl protecting group on the side chain.
[0051] In a preferred embodiment of the present invention, the selective deprotection is accomplished using p-toluenesulfonic acid.
[0052] In a preferred embodiment of the present invention, the side chain includes (2R, 4S, 5R)-3-tert-butoxycarbonyl-2-(4'-methoxyphenyl)-4-phenyl-1,3-oxazolidine-5-carboxylic acid, (2R, 4S, 5R)-3-tert-butoxycarbonyl-2-dimethyl-4-phenyl-1,3-oxazolidine-5-carboxylic acid, (3R, 4S)-3-(1-ethoxyethyl)-4-phenyl-N-tert-butoxycarbonyl-2-azetidinone, (2R, 3S)-N-tert-butoxycarbonyl-O-(1-ethoxyethyl)-3-phenylisoserine.
[0053] The present invention solves the defects existing in the background technology and has the following beneficial effects:
[0054] (1) The present invention overcomes the shortcomings of previous process conditions such as complex reaction conditions, high reagent toxicity, low product yield, great purification difficulty, and high production cost;
[0055] (2) The present invention uses 9-dihydro-13-acetylbaccatin III as the starting material for synthesis, which expands the source of raw materials for the synthesis of cabazitaxel and simplifies the process;
[0056] (3) The present invention eliminates the highly toxic and highly polluting chemicals used in the traditional cabazitaxel synthesis process and creatively uses low-toxic or non-toxic, more environmentally friendly synthesis reagents;
[0057] (4) The product purity obtained by the present invention is higher, reaching above 99.5%. BRIEF DESCRIPTION OF THE DRAWINGS
[0058] Figure 1 It is a key intermediate of the preferred embodiment of the present invention;
[0059] Figure 2 It is a synthesis path diagram of a preferred embodiment of the present invention. DETAILED DESCRIPTION
[0060] The technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. In the description of the present invention, the reference to "embodiment", "one embodiment" or "other embodiments" means that the specific features, structures or characteristics described in conjunction with the embodiment are included in at least some embodiments, but not necessarily all embodiments. All other embodiments obtained by ordinary technicians in the field without making creative work are within the scope of protection of the present invention.
[0061] The synthetic route of Cabazitaxel includes the following steps:
[0062] 9-dihydro-13-acetylbaccatin III (9-DHAB) was dissolved in methanol, mixed with tetrabutylammonium iodide and sodium methoxide for reaction, and then water and dichloromethane were added to terminate the reaction. The dichloromethane portion was collected and purified to obtain 9-dihydro-10-deacetyl-13-acetylbaccatin III (IM1) solid; IM1 was dissolved in THF, tetrabutylammonium iodide and dimethyl carbonate were added, and a mineral oil solution of sodium cyanide was dropped into it. After the reaction was completed, water and dichloromethane were added to terminate the reaction. The organic phase was collected and purified to obtain 9-dihydro-7,10-dimethoxy-13-acetylbaccatin III (9-dihydro-7,10-dimethoxy-13-acetylbaccatin III III, IM2) solid; Dess-Martin periodinane was added to the dichloromethane solution containing IM2, and after the reaction was completed, it was purified by silica gel column chromatography to obtain 7,10-dimethoxy-13-acetylbaccatin III (7,10-dimethoxy-13-acetylbaccatin III, IM3); IM3 was dissolved in ethanol, hydrazine hydrate was added, and the reaction was carried out at room temperature overnight and then allowed to stand for crystallization to obtain 7,10-dimethoxybaccatin III (7,10-dimethoxybaccatin III, IM4) solid; to a dichloromethane solution containing (2R,4S,5R)-3-tert-butoxycarbonyl-2-(4'-methoxyphenyl)-4-phenyl-1,3-oxazolidine-5-carboxylic acid {(2R,4S,5R)-3-tert-butoxycarbonyl-2-(4'-methoxyphenyl)-4-phenyl-1,3-oxazolidine-5-carboxylic acid, docetaxel side chain} and IM4 in anhydrous toluene solution, and stir at room temperature until the reaction is complete, then quench the reaction mixture, concentrate the organic phase and purify to obtain {7,10-dimethoxybaccatin III-13-(2R,4S,5R)-3-tert-butyloxycarbonyl-2-(4'-methoxyphenyl)-4-phenyl-1,3-oxazolidine-5-carboxylate, IM5}; add p-TsOH to the methanol solution of IM5 and stir, after the reaction is complete, quench the reaction mixture with brine, concentrate the organic phase and purify by reverse phase column chromatography to obtain cabazitaxel with a purity greater than 99.5%.
[0063] Embodiment 1:
[0064]
[0065] Preparation of the key intermediate 10-deacetyl-9-dihydro-13-acetylbaccatin III (IM1) (Formula 5):
[0066] Dissolve 50 grams (79.3 mmol) of 9-dihydro-13-acetylbaccatin III (9-DHAB) in 700 ml of methanol (CH3OH). After 9-DHAB is completely dissolved, add 5.9 grams of tetrabutylammonium iodide (Bu4NI, 15.9 mmol, 0.2 equivalents), stir and lower the temperature to 0°C, then add sodium methoxide (CH3ONa, 8.6 g, 158.6 mmol, 2 equivalents) at once, continue stirring and slowly raise the temperature to room temperature, continue to react at this temperature for about 1.5 hours until TLC inspection shows that 9-DHAB has completely reacted, add 300 ml of water and 500 dichloromethane (DCM) to the reaction solution and continue stirring for 20 minutes, stop stirring, and stand for 2 hours. Filter out the white precipitate and wash with 100 ml of water, let the filtrate stand for stratification, wash the organic phase with 100 ml of water, and then concentrate under reduced pressure to about 50 ml, and let the concentrate stand for crystallization. The white crystals were filtered out and washed with 100 ml of purified water. The two white crystalline solids were combined and dried to obtain 40 g of IM1 white solid (IM1, yield 87%). 1 H-NMR(CDCl3)δ8.11(d,2H),7.62(t,lH),7.49(t,2H),6.21(t,lH),5.78(d,lH),4.96(d, lH),4.93(d,lH),4.89(d,1H),4.40(dd,lH),4.35(d,lH),4.32(d,lH),4.20(d,lH),3.51 (d,OH),3.24(d,OH),3.08(d,lH),2.56(ddd,lH),2.30(s,3H),2.25-2.0(m,2H),2.21(s, 3H),1.96(dd,lH),1.87(d,3H),1.85(dd,1H),1.73(s,3H),1.62(s,3H),1.33(s,3H)ppm.
[0067] Embodiment 2:
[0068]
[0069] Preparation of 7,10-dimethoxy-10-deacetyl-9-dihydro-13-acetylbaccatin III (IM2) (Formula VI):
[0070] Compound 10-deacetyl-9-dihydro-13-acetylbaccatin III (IM1, 135 mmol, 79 g) was dissolved in 700 ml of anhydrous tetrahydrofuran (THF), cooled to -60°C, and then a catalytic amount of tetrabutylammonium iodide (Bu4NI, 10 g, 27 mmol) and dimethyl carbonate [(CH3O)2CO, 62 g, 695 mmol, 5 equiv] were added. After stirring for about 10 minutes, a mineral oil solution of sodium cyanide (NaH, 13 g, 540 mmol, 4 equiv) was then added dropwise. Stirring was continued at low temperature for one hour, and then the temperature was slowly raised to 0°C and maintained until the reaction was completed by TLC. Stirring was stopped. A mixed solution of 500 ml of purified water and 500 ml of dichloromethane was added to the reactor and continued to stir for 5 minutes, and then allowed to stand for stratification. The organic phase was collected and then washed with 1000 ml of saturated sodium chloride aqueous solution. The organic phase was then concentrated to dryness under reduced pressure. The residue was dissolved with a small amount of acetone and then separated and purified on a reverse phase polystyrene / divinylbenzene polymer resin column. The IM2-containing portion was collected and concentrated to obtain 68.5 g of white IM2 solid (yield 63%). 1 H-NMR: δ8.05(d,2H),7.60(t,lH),7.45(t,2H),6.18(t,lH),5.75(d,lH),4.96(d,lH),4. 85(d,lH),4.79(d,1H),4.40(dd,lH),4.35(d,lH),4.30(d,lH),4.12(d,lH),3.41(s,3H,O Me),3.24(s,3H,OMe),3.08(d,lH),2.67(ddd,lH),2.30(s,3H),2.25-2.0(m,2H),2.21(s ,3H),1.96(dd,lH),1.78(d,3H),1.85(dd,1H),1.73(s,3H),1.65(s,3H),1.17(s,3H)ppm.
[0071] Embodiment three:
[0072]
[0073] Preparation of 7,10-dimethoxy-10-deacetyl-13-acetylbaccatin III (IM3) (Formula VII):
[0074] Dess-Martin oxidant (24 g, 50 mmol) was added to a stirred dichloromethane solution of 7,10-dimethoxy-10-deacetyl-9-dihydro-13-acetylbaccatin III (IM2, 25 g, 20 mmol), and the mixture was stirred at room temperature overnight. After TLC showed that the reaction was complete, water was added to terminate the reaction, and then the organic phase was washed twice with purified water and then dehydrated with anhydrous sodium sulfate. The organic phase was concentrated to dryness in vacuo, and the residue was purified by flash chromatography to obtain 7,10-dimethoxy-10-deacetyl-13-acetylbaccatin III (IM3, 22.5 g, yield 91%). 1 H-NMR (400MHz, CDCl3): δ8.10(d,2H),7.60(t,lH),7.45(t,2H),6.23(t,1H)5.75(d,lH),4.9 6(d,lH),4.93(s,lH),4.86(t,1H),4.40(d,lH),4.35(d,1H),4.19(d,lH),3.90(dd,lH),3.85 (d,1H),3.45(S,3H,OMe),3.28(S,3H,OMe),2.56(ddd,lH),2.30(s,3H),2.25-2.0(m,2H),2.2 1(s,3H),1.96(dd,lH),1.85(dd,1H),2.04(s,3H),1.65(s,3H),1.20(s,3H),1.05(s,3H)ppm.
[0075] Embodiment 4:
[0076]
[0077] Preparation of 7,10-dimethoxy-10-deacetylbaccatin III (IM4) (Formula VIII):
[0078] 40g of 7,10-dimethoxy-10-deacetyl-13-acetylbaccatin III (IM3, 48.5mmol) was dissolved in 1.7L of 95% ethanol and stirred. 235ml of 85% hydrazine hydrate was added to the stirred solution. The mixture was stirred at room temperature overnight. The next day, when TLC showed that all the starting materials had been consumed, 3L of purified water was added to the mixed solution and continued to stir for one hour, and then allowed to stand for crystal formation. The white solid was filtered, the filter cake was washed with 100ml of purified water and dried in a vacuum drying oven at 50°C to obtain 34g of 7,10-dimethoxy-10-deacetylbaccatin III (IM4) as a white solid, with a yield of 89%.
[0079] 1H-NMR (400MHz, CDCl3): δ8.05(d,2H),7.56(t,lH),7.45(t,2H),5.56(d,lH),4.96( d,lH),4.83(s,lH),4.80(t,1H),4.30(d,lH),4.12(d,lH),3.90(dd,lH),3.85(d,1H ),3.45(S,3H,OMe),3.28(S,3H,OMe),2.56(ddd,lH),2.30(s,3H),2.25-2.0(m,2H), 2.05(s,3H),1.96(dd,lH),1.85(dd,1H),1.65(s,3H),1.18(s,3H),1.03(s,3H)ppm.
[0080] Embodiment five:
[0081]
[0082] Preparation of 7,10-dimethoxy-10-deacetylbaccatin III-13-tert-butyloxycarbonyl-2-(4'-methoxyphenyl)-4-phenyl-1,3-oxazolidine-5-carboxylate (IM5) (Formula 9):
[0083] To a stirred solution of (2R,4S,5R)-3-tert-butyloxycarbonyl-2-(4'-methoxyphenyl)-4-phenyl-1,3-oxazolidine-5-carboxylic acid (docetaxel side chain) (20 g, 0.3 mol) and IM4 (20.0 g, 0.15 mol) in anhydrous toluene were added DMAP (0.6 eq.) and DCC (3 eq.). The mixture was stirred at room temperature for 2 hours. When TLC showed complete disappearance of the starting material, the reaction mixture was quenched with water. The organic phase was collected and washed with water and brine, then dried over anhydrous sodium sulfate (Na2SO4), filtered, and the filtrate was concentrated in vacuo. The residue was purified by silica gel column chromatography to give IM5 (21 g, yield 90%). 1H-NMR (400MHz, CDCl3): δ7.96(d,2H),7.58(t,1H),7.43(t,2H),7.25-7.40(m,7H),6.88(d,2H),6.33(s,1 H),6.07(t,1H),5.53(d,1H),5.36(m,1H),4.85(bd,1H),4.67(s,1H),4.53(d,1H),4.16(d,1H),4.06(d,1 H),3.76(s,3H),3.73(m,1H),3.64(d,1H),3.35(s,3H),3.22(s,3H),2.60(m,1H),2.15(dd,1H),2.14(s,3 H),2.02(dd,1H),1.78(s,3H),1.65-1.85(m,1H),1.63(s,3H),1.17(s,3H),1.10(s,3H),1.02(s,9H)ppm.
[0084] Embodiment six:
[0085]
[0086] Preparation of Cabazitaxel (Formula 10):
[0087] To a solution of IM5 (5.0 g, 5.5 mmol) in methanol (50 ml) was added p-TsOH (1 g, 6 mmol), and the mixture was stirred at room temperature for 3 hours. When TLC showed that the starting material disappeared, the reaction mixture was quenched with NaHCO3 (0.5 g), then concentrated in vacuo, and the residue was purified by column chromatography to give Cabazitaxel (IM6, 2.8 g, yield 78.0%). 1 H-NMR (400MHz, CDCl3): δ8.10(d,2H),7.65(t,1H),7.52(t,2H),7.30-7.50(m,5H),6.24(t, 1H),5.65(d,1H),5.47(d,1H),4.65(mt,1H),4.33(d,1H),4.20(d,1H),3.88(dd,1H),3.85( d,1H),3.48(mt,1H),3.48(s,3H),3.35(s,3H),2.70(m,1H),2.39(s,3H),2.31(m,2H),1.91 (s,3H),1.82(mt,1H),1.75(s,3H),1.70(s,1H),1.39(s,9H),1.25(s,3H),1.23(s,3H)ppm.
[0088] The above is based on the ideal embodiment of the present invention. Through the above description, relevant personnel can make various changes and modifications without departing from the technical concept of the present invention. The technical scope of the present invention is not limited to the content in the specification, and the technical scope must be determined according to the scope of the claims.
Claims
1. A compound having a structure shown in Formula 1: wherein R1 is methyl; R2 is methyl; R3 is acetyl.
2. The synthetic route of Cabazitaxel, It is characterized in that The following steps are involved: (a): removing the 10-position acetyl group of 9-dihydro-13-acetylbaccatin III to obtain 9-dihydro-10-deacetyl-13-acetylbaccatin III; (b): protecting the 7-, 10-hydroxyl groups of 9-dihydro-10-deacetyl-13-acetylbaccatin III with a suitable protecting group to obtain a protected intermediate; (c): oxidizing the 9-hydroxyl group of the protected intermediate with a suitable oxidant; The protecting group is methyl; The synthetic route further includes the step of removing the 13-acetyl group of the intermediate 7,10-dimethoxy-10-deacetyl-13-acetylbaccatin III; The synthetic route further includes the step of adding a suitable side chain to the 13-position of 7,10-dimethoxy-10-deacetylbaccatin III, and selectively deprotecting to obtain the target compound; The selective deprotection is to remove the p-methoxybenzoyl protecting group on the side chain.
3. In the synthesis route described in claim 2, the oxidant is selected from: Dess-Martin periodinane, Colin periodinane, Sway periodinane, John periodinane, pyridinium chlorochromate, pyridinium dichromate, chromium dioxide and tetra-n-propylammonium perruthenate.
4. In the synthesis route described in claim 2, the removal of the 13-acetyl group is accomplished by using a strong base, and the strong base is selected from: n-butyl lithium, methyl lithium, red aluminum, sodium borohydride, and hydrazine hydrate.
5. In the synthetic route described in claim 2, the selective deprotection is accomplished using p-toluenesulfonic acid.
6. In the synthetic route described in claim 2, the side chain is selected from: (2R, 4S, 5R)-3-tert-butoxycarbonyl-2-(4'-methoxyphenyl)-4-phenyl-1,3-oxazolidine-5-carboxylic acid, (2R, 4S, 5R)-3-tert-butoxycarbonyl-2-dimethyl-4-phenyl-1,3-oxazolidine-5-carboxylic acid, (3R, 4S)-3-(1-ethoxyethyl)-4-phenyl-N-tert-butoxycarbonyl-2-azetidinone, (2R, 3S)-N-tert-butoxycarbonyl-O-(1-ethoxyethyl)-3-phenylisoserine.
